Jazz Pharmaceuticals (JAZZ) Enterprise Value (2010 - 2026)

Jazz Pharmaceuticals' Enterprise Value history runs 17 years deep, the most recent figure standing at -$1.8 billion for Q1 2026.

• On a quarterly basis, Enterprise Value rose 0.95% year-over-year to -$1.8 billion in Q1 2026; TTM through Mar 2026 was -$1.8 billion, a 0.95% increase from a year earlier, with the FY2025 full-year figure at -$1.4 billion, up 42.31% from the prior year.
• Enterprise Value fell to -$1.8 billion in Q1 2026 per JAZZ's latest filing, from -$1.4 billion in the prior quarter.
• Across five years, Enterprise Value topped out at -$490.8 million in Q1 2022 and bottomed at -$2.4 billion in Q4 2024.
• The 5-year median for Enterprise Value is -$1.3 billion (2023), against an average of -$1.4 billion.
• Across the five-year window, Enterprise Value jumped 76.6% in 2022 and tumbled 137.94% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$881.5 million in 2022, then plunged by 70.88% to -$1.5 billion in 2023, then sank by 60.18% to -$2.4 billion in 2024, then surged by 42.31% to -$1.4 billion in 2025, then slumped by 32.5% to -$1.8 billion in 2026.
• Per Business Quant, the three latest JAZZ Enterprise Value figures stand at -$1.8 billion (Q1 2026), -$1.4 billion (Q4 2025), and -$1.3 billion (Q3 2025).